Antiretroviral Treatments

ANTIRETROVIRAL TREATMENTS
ANTIRETROVIRAL TREATMENTS
Generic Brand Strength Form Usual Dose
CCR5 Co-Receptor Antagonists
maraviroc (MVC) Selzentry 150mg, 300mg tabs Adults: ≥16yrs: Concomitant potent CYP3A inhibitors (eg, PIs [except tipranavir/ritonavir], delavirdine, elvitegravir/ritonavir, ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin, boceprevir) (with or without a potent CYP3A inducer): 150mg twice daily. Other concomitant drugs, including tipranavir/ritonavir, nevirapine, raltegravir, NRTIs, enfuvirtide: 300mg twice daily. Concomitant potent CYP3A inducers (eg, efavirenz, rifampin, etravirine, carbamazepine, phenobarbital, phenytoin) (without a potent CYP3A inhibitor): 600mg twice daily. Severe renal dysfunction or ESRD (CrCl <30mL/min) (without potent CYP3A inhibitors or inducers): reduce dose from 300mg twice daily to 150mg twice daily if postural hypotension occurs.
Children: <16yrs: not established.
Fusion Inhibitors
enfuvirtide
(ENF, T‑20)
Fuzeon 90mg/mL pwd for SC inj after reconstitution Adults: ≥16yrs: 90mg twice daily via SC inj into upper arm, anterior thigh, or abdomen
Children: <6yrs: not established. ≥6−16yrs: Limited data available; recommended 2mg/kg (max 90mg) twice daily.
HIV-1 Integrase Strand Transfer Inhibitors
dolutegravir Tivicay 10mg, 25mg, 50mg tabs Adults: Treatment-naïve or treatment-experienced INSTI-naïve: 50mg once daily; when concomitant with certain UGT1A or CYP3A inducers: 50mg twice daily. INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50mg twice daily.
Children: <30kg or INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir): not established. Treatment-naïve or treatment-experienced INSTI-naïve: (30–<40kg): 35mg once daily; (≥40kg): 50mg once daily; when concomitant with certain UGT1A or CYP3A inducers: increase weight-based dose to twice daily.
elvitegravir Vitekta 85mg, 150mg tabs Adults: 85mg once daily regimen: in combination with atazanavir 300mg once daily + ritonavir 100mg once daily; or with lopinavir 400mg twice daily + ritonavir 100mg twice daily.
150mg once daily regimen: in combination with darunavir 600mg twice daily + ritonavir 100mg twice daily; or with fosamprenavir 700mg twice daily + ritonavir 100mg twice daily; or with tipranavir 500mg twice daily + ritonavir 200mg twice daily.
All regimens must be co‑administered with another antiretroviral agent.
Children: Not established.
raltegravir potassium (RAL) Isentress 25mg, 100mg+ chew tabs Adults: 400mg tab twice daily (avoid dosing prior to dialysis). Concomitant rifampin: 800mg twice daily.
Children: <4wks: not established. ≥4wks (≥25kg): one 400mg film-coated tab twice daily. If unable to swallow, can use chew tabs: (25−<28kg): 150mg twice daily; (28−<40kg): 200mg twice daily; ≥40kg: 300mg twice daily. Chew tabs max dose: 300mg twice daily.
400mg tabs
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
delavirdine mesylate (DLV) Rescriptor 100mg, 200mg tabs Adults: ≥16yrs: 400mg 3 times daily.
Children: <16yrs: not established.
efavirenz (EVF) Sustiva 50mg, 200mg caps Adults and Children: Once daily on an empty stomach, preferably at bedtime. Consider pretreating with antihistamine (for children) or steroid to minimize rash.
<3mos or <3.5kg: not recommended. >3mos: (3.5−<5kg): 100mg; (5−<7.5kg): 150mg; (7.5−<15kg): 200mg; (15−<20kg): 250mg; (20−<25kg): 300mg; (25−<32.5kg): 350mg; (32.5−<40kg): 400mg; (>40kg) and adults: 600mg. Concomitant voriconazole: increase voriconazole maintenance dose to 400mg every 12hrs and decrease efavirenz dose to 300mg once daily using caps.
Concomitant rifampin (≥50kg): increase efavirenz dose to 800mg once daily.
600mg tabs
etravirine (ETR) Intelence 25mg+, 100mg, 200mg tabs Adults and Children: <6yrs or <16kg: not established. Take twice daily after meals.
≥6−<18yrs: (≥16−<20kg): 100mg; (≥20−<25kg): 125mg; (≥25−<30kg): 150mg; (≥30kg) or adults: 200mg.
nevirapine (NVP) Viramune 200mg+ tabs Adults: ≥16yrs: Initially 200mg once daily for 14 days; then 200mg twice daily.
Dialysis: Give additional 200mg after dialysis.
Children: <15days: not recommended. ≥15days: Initially 150mg/m² once daily for 14 days, then increase to 150mg/m² twice daily.
Both: If mild-to-moderate rash occurs during the 14‑day lead‑in period, do not give twice-daily regimen until rash has resolved. Max lead‑in period: 28 days, consider alternative regimen. If severe rash or hepatic event occurs, discontinue permanently. Max 400mg/day. Retitrate if stopped for >7 days.
50mg/
 
5mL
oral susp
Viramune XR 400mg ext-rel tabs Adults: Initially Viramune 200mg once daily for 14 days, then Viramune XR 400mg once daily. If mild-to-moderate rash develops during the 14‑day lead in period, do not start Viramune XR until rash has resolved. Lead‑in period not necessary if patient already on a regimen of immediate-release Viramune twice daily. Max once-daily lead in period: 28 days; consider alternative regimen. If severe rash or hepatic event occurs, discontinue permanently. Retitrate if stopped for >7 days.
Children: <6yrs: not recommended. ≥6–<18yrs: Initially 150mg/m2 Viramune oral susp or IR tabs once daily for 14 days (max 200mg/day); then Viramune XR dose based on BSA: 0.58–0.83m2: 200mg once daily; 0.84–1.16m2: 300mg once daily; ≥1.17m2: 400mg once daily. All: max 400mg/day.
rilpivirine Edurant 25mg tabs Adults and Children: <12yrs: not recommended. ≥12yrs (≥35kg): 25mg once daily with a meal.
Concomitant rifabutin: 50mg once daily; decrease to 25mg once daily when rifabutin is stopped.
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
abacavir sulfate (ABC) Ziagen 300mg tabs Adults: >16yrs: 300mg twice daily or 600mg once daily. Mild hepatic impairment: 200mg twice daily.
Children: <3mos: not established. ≥3mos (oral soln): 8mg/kg twice daily or 16mg/kg once daily; max 600mg daily. If able to swallow tabs: 14−<20kg: 300mg once daily or 150mg twice daily; ≥20−<25kg: 450mg once daily or 150mg in the AM and 300mg in the PM; ≥25kg: use Adult dose.
20mg/mL oral soln1
abacavir sulfate (ABC)/
lamivudine (3TC)
Epzicom ABC/
 
3TC:
600mg/
 
300mg
tabs Adults: >18yrs: 1 tab daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended.
Children: ≤18yrs: not recommended.
abacavir sulfate (ABC)/
lamivudine (3TC)/
zidovudine (ZDV)
Trizivir ABC/
 
3TC/
  
ZDV:
300mg/
 
150mg/
  300mg
tabs Adults: <40kg: not recommended. ≥40kg: 1 tab twice daily.
Children: Not recommended.
didanosine (ddl) Videx EC 125mg, 200mg, 250mg, 400mg e‑c del‑rel caps Adults and Children: Take once daily on an empty stomach. <20kg: use oral soln. 20−<25kg: 200mg. 25−<60kg: 250mg. ≥60kg: 400mg.
Renal impairment (CrCl 30−59mL/min): <60kg: 125mg. ≥60kg: 200mg. CrCl 10−29mL/min: 125mg. CrCl <10mL/min or dialysis: <60kg: Use oral soln; ≥60kg: 125mg.
Videx Pediatric Pwd for Oral Soln 4g pediatric pwd for oral soln after reconstitution Adults: Take on an empty stomach. <60kg: 125mg twice daily or 250mg once daily. ≥60kg: 200mg twice daily or 400mg once daily.
Renal impairment (CrCl 30−59mL/min): <60kg: 150mg once daily or 75mg twice daily; ≥60kg: 200mg once daily or 100mg twice daily; CrCl 10−29mL/min: <60kg: 100mg once daily; ≥60kg: 150mg once daily; CrCl <10mL/min or dialysis: <60kg: 75mg once daily; ≥60kg: 100mg once daily.
Children: <2wks: not recommended. 2wks−8mos: 100mg/m² twice daily. ≥8mos: 120mg/m² twice daily.
Renal impairment: Consider reducing dose and/or increasing dosing interval. See full labeling.
emtricitabine (FTC) Emtriva 200mg caps Adults: ≥18yrs: 200mg once daily. Renal impairment (CrCl 30−49mL/min): 200mg every 48hrs; (CrCl 15−29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.
Children: <3mos: not recommended. 3mos−17yrs: ≤33kg: use soln form. >33kg: 200mg once daily. Renal impairment: Reduce dose or prolong dosing interval.
10mg/mL oral soln Adults: ≥18yrs: 240mg once daily. Renal impairment: (CrCl 30−49mL/min): 120mg once daily; (CrCl 15−29mL/min): 80mg once daily; (CrCl <15mL/min): 60mg once daily.
Children: <3mos: 3mg/kg once daily. 3mos−17yrs: 6mg/kg once daily; max 240mg/day. >33kg: May use cap form. Renal impairment: Reduce dose or prolong dosing interval.
emtricitabine (FTC)/
tenofovir disoproxil fumarate (TDF)
Truvada 100mg/150mg, 133mg/200mg,
167mg/250mg, 200mg/300mg
tabs Adults: ≥35kg: 200mg/300mg once daily. Renal impairment: CrCl 30–49mL/min: 200mg/300mg every 48hrs; CrCl <30mL/min, hemodialysis: not recommended.
Children: <17kg: not established. 17–<22kg: 100mg/150mg once daily. 22–<28kg: 133mg/200mg once daily. 28–<35kg: 167mg/250mg once daily. ≥35kg: 200mg/300mg once daily.
lamivudine (3TC) Epivir 150mg+, 300mg tabs Adults: CrCl ≥50mL/min: 300mg once daily or 150mg twice daily; CrCl 30−49mL/min: 150mg once daily; CrCl 15−29mL/min: 150mg for 1st dose then 100mg once daily; CrCl 5−14mL/min: 150mg for 1st dose then 50mg once daily; CrCl <5mL/min: 50mg for 1st dose then 25mg once daily.
Children: <3mos: not established. ≥3mos (oral soln): 4mg/kg twice daily or 8mg/kg once daily; max 300mg/day. Tabs: 14−<20kg: 150mg once daily or 75mg twice daily; ≥20−<25kg: 225mg once daily or 75mg in the AM and 150mg in the PM; ≥25kg: 300mg once daily or 150mg twice daily. Renal impairment: reduce dose or prolong dosing interval.
10mg/mL oral soln
lamivudine (3TC)/ zidovudine (ZDV) Combivir 3TC/
 
ZDV:
150mg/
 
300mg
tabs Adults: 1 tab twice daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended.
Children: Not recommended.
stavudine (d4T) Zerit 15mg, 20mg, 30mg, 40mg caps Adults: ≥60kg: 40mg every 12hrs; <60kg: 30mg every 12hrs.
Renal impairment: ≥60kg (CrCl 26−50mL/min): 20mg every 12hrs; (CrCl 10−25mL/min), dialysis: 20mg every 24hrs. <60kg (CrCl 26−50mL/min): 15mg every 12hrs; (CrCl 10−25mL/min), dialysis: 15mg every 24hrs.
Children: ≤13 days: 0.5mg/kg every 12hrs. ≥14 days: (<30kg): 1mg/kg every 12hrs. ≥30kg: as adult.
Renal impairment: Reduce dose or increase dosing interval.
1mg/mL pwd for oral soln after reconsti-
tution
tenofovir disoproxil fumarate (TDF) Viread 150mg, 200mg, 250mg, 300mg tabs Adults: ≥12yrs (≥35kg): 300mg once daily. Renal impairment: CrCl 30–49mL/min: 300mg every 48hrs; CrCl 10–29mL/min: 300mg every 72–96hrs; hemodialysis: 300mg every 7 days or after a total of 12hrs of dialysis; CrCl <10mL/min: not recommended.
40mg/g oral pwd Children: <2yrs: not established.
≥2yrs: 8mg/kg once daily; max 300mg/day. ≥17kg: may use tabs if able to swallow. 17–<22kg: 150mg once daily. 22–<28kg: 200mg once daily. 28–<35kg: 250mg once daily. ≥35kg: 300mg once daily. See full labeling for additional dosing based on body wt.
zidovudine (ZDV) Retrovir 100mg caps Adults: ≥18yrs: 600mg daily in divided doses. End‑stage renal disease on dialysis: 100mg every 6−8hrs. Vertical transmission, severe anemia and/or neutropenia: See full labeling.
300mg tabs Children: <6wks and/or for vertical transmission: See full labeling.
6wks−<18yrs: (4−<9kg): 24mg/kg/day (12mg/kg twice daily or 8mg/kg 3 times daily);
(≥9−<30kg): 18mg/kg/day (9mg/kg twice daily or 6mg/kg 3 times daily);
(≥30kg): 600mg/day (300mg twice daily or 200mg 3 times daily).
Alternative dosing based on BSA: 240mg/m² twice daily or 160mg/m² 3 times daily.
50mg/
 
5mL
syrup
10mg/mL soln for IV inj after dilution Adults: Give by IV infusion over 1hr; use only until oral therapy can be given. 1mg/kg 5−6 times daily. End‑stage renal disease on dialysis: 1mg/kg every 6−8hrs. Vertical transmission, severe anemia and/or neutropenia: See full labeling.
Children: Vertical transmission: See full labeling.
Pharmacokinetic Enhancer
cobicistat Tybost 150mg tabs Adults: Must be co‑administered at same time as atazanavir or darunavir.
≥18yrs: 150mg once daily with atazanavir 300mg once daily (if treatment-naive or experienced) or with darunavir 800mg once daily (if treatment-naive or experienced with no darunavir resistance associated substitutions).
Children: <18yrs: not established.
Protease Inhibitors (PIs)
atazanavir sulfate (ATV) Reyataz 150mg, 200mg, 300mg caps Adults: Take with food.
Treatment-naive: atazanavir 300mg + ritonavir 100mg once daily;
atazanavir 400mg once daily if unable to tolerate ritonavir; concomitant efavirenz: atazanavir 400mg + ritonavir 100mg once daily + efavirenz 600mg at bedtime (on an empty stomach);
ESRD with hemodialysis: atazanavir 300mg + ritonavir 100mg; hepatic impairment: (mild): 400mg once daily; (moderate): 300mg once daily; (severe): not recommended.
Treatment-experienced: atazanavir 300mg + ritonavir 100mg once daily;
concomitant H2‑blocker and tenofovir: atazanavir 400mg + ritonavir 100mg once daily.
Concomitant tenofovir: atazanavir 300mg + tenofovir 300mg + ritonavir 100mg once daily.
Pregnancy: atazanavir 300mg + ritonavir 100mg once daily; concomitant H2‑blocker or tenofovir (2nd or 3rd trimester): atazanavir 400mg + ritonavir 100mg. See full labeling.
Children: <6yrs: not recommended. Take with food. Take once daily.
6−18yrs: 15−<20kg: atazanavir 150mg + ritonavir 100mg; 20−<40kg: atazanavir 200mg + ritonavir 100mg; ≥40kg: atazanavir 300mg + ritonavir 100mg.
Treatment-naive: ≥13yrs and ≥40kg who are unable to tolerate ritonavir: atazanavir 400mg once daily.
Patients ≥13yrs and ≥40kg receiving concomitant tenofovir, H2‑blockers, or PPIs: take atazanavir with ritonavir. See full labeling.
50mg oral pwd3
darunavir ethanolate (DRV) Prezista 75mg, 150mg, 400mg, 600mg, 800mg tabs Adults: ≥18yrs: Treatment-naive or treatment-experienced with no darunavir resistance associated substitutions: darunavir 800mg + ritonavir 100mg once daily.
Treatment-experienced with at least one darunavir resistance associated substitution: darunavir 600mg + ritonavir 100mg twice daily.
Children: <3yrs: not recommended. ≥3−<18yrs: Treatment-naive or treatment-experienced with no darunavir resistance associated substitutions: 10−<15kg: darunavir 35mg/kg + ritonavir 7mg/kg once daily; ≥15−<30kg: darunavir 600mg + ritonavir 100mg once daily; ≥30−<40kg: darunavir 675mg + ritonavir 100mg once daily; ≥40kg: darunavir 800mg + ritonavir 100mg once daily. Treatment-experienced with at least one darunavir resistance associated substitution: 10−<15kg: darunavir 20mg/kg + ritonavir 3mg/kg twice daily; ≥15−<30kg: darunavir 375mg + ritonavir 48mg twice daily; ≥30−<40kg: darunavir 450mg + ritonavir 60mg twice daily; ≥40kg: darunavir 600mg + ritonavir 100mg twice daily.
See full labeling for complete weight based dosing.
Both: Take with food.
Severe hepatic impairment: not recommended.
100mg/
 
mL
oral susp
fosampre-
navir calcium (FOS‑APV)
Lexiva 700mg tabs Adults: Oral susp: take without food.
Therapy-naive: 1.4g twice daily; or fosamprenavir 1.4g + ritonavir 200mg once daily; or fosamprenavir 1.4g + ritonavir 100mg once daily; or fosamprenavir 700mg + ritonavir 100mg twice daily.
PI‑experienced: fosamprenavir 700mg + ritonavir 100mg twice daily.
Hepatic dysfunction: See full labeling.
Children: PI‑naive (<4wks) or PI‑experienced (<6mos): not recommended.
Oral susp: Take twice daily with food.
PI‑naive (≥4wks−18yrs) or PI‑experienced (≥6mos): <11kg: fosamprenavir 45mg/kg + ritonavir 7mg/kg; 11−<15kg: fosamprenavir 30mg/kg + ritonavir 3mg/kg; 15−<20kg: fosamprenavir 23mg/kg + ritonavir 3mg/kg; ≥20kg: fosamprenavir 18mg/kg + ritonavir 3mg/kg. PI‑naive (≥2yrs): fosamprenavir 30mg/kg.
Both: If emesis occurs within 30min after dosing, re‑dose. Do not exceed adult dose. See full labeling.
50mg/mL oral susp
indinavir sulfate (IDV) Crixivan 200mg, 400mg caps Adults: Take with water on an empty stomach or with a light meal. 800mg every 8hrs.
Concomitant rifabutin: 1g every 8hrs and reduce rifabutin dose by ½.
Concomitant ketoconazole, itraconazole, delavirdine, or hepatic insufficiency: 600mg every 8hrs.
Children: Not established. 3−18yrs: 500mg/m² every 8hrs has been used; see full labeling.
lopinavir (LPV)/ ritonavir (RTV) Kaletra LPV/
 
RTV: 100mg/
 
25mg, 200mg/
 
50mg
tabs Adults: Oral soln: take with food. 400mg/100mg twice daily or 800mg/200mg once daily.
≥3 lopinavir resistance-associated substitutions or in combination with carbamazepine, phenobarbital, phenytoin: once daily admin not recommended.
Concomitant efavirenz, nevirapine, or nelfinavir: 500/125mg (two 200/50mg tabs and one 100/25mg tab) or 520/130mg (6.5mL) twice daily.
Pregnancy: once daily & soln not recommended.
Children: <42wks postmenstrual age or <14 days postnatal: not recommended.
14days–6mos: 16/4mg/kg or 300/75mg/m2 twice daily. Do not administer with efavirenz, nevirapine, or nelfinavir. ≥6mos: 230/57.5mg/m2 twice daily or <15kg: 12/3mg/kg twice daily;
≥15–40kg: 10/2.5mg/kg twice daily;
>40kg: max 400/100mg twice daily.
Concomitant efavirenz, nevirapine, or nelfinavir: ≥6mos: 300/75mg/m2 twice daily or <15kg: 13/3.25mg/kg twice daily; ≥15–45kg: 11/2.75mg/kg twice daily; >45kg: max oral soln: 520/130mg (6.5mL) twice daily; or max tabs: 500/125mg twice daily. See full labeling.
LPV/
 
RTV: 80mg/
 
20mg per mL
oral soln2,5
nelfinavir mesylate (NFV) Viracept 250mg, 625mg tabs Adults and Children: Take with food.
<2yrs: not recommended.
2−13yrs: 45−55mg/kg twice daily or 25−35mg/kg 3 times daily; max 2.5g/day. >13yrs: 1.25g twice daily or 750mg 3 times daily. Reduce concomitant rifabutin dose by ½ and give nelfinavir 1.25g twice daily.
50mg/g oral pwd3
ritonavir (RTV) Norvir 100mg tabs, soft gel caps2,5 Adults: Take with meals. Initially at least 300mg twice daily, increase every 2−3 days by 100mg twice daily to 600mg twice daily.
Concomitant other Pls (eg, atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir): Reduce ritonavir dose. See full labeling.
80mg/mL oral soln2 Children: <1mo or before postmenstrual age <44wks: not recommended. >1mo: Initially 250mg/m² twice daily; increase every 2−3 days by 50mg/m² twice daily to 350−400mg/m² twice daily; max 600mg twice daily.
saquinavir mesylate (SQV) Invirase 500mg tabs Adults: Take within 2hrs after a meal.
≥16yrs: saquinavir 1g twice daily + ritonavir 100mg twice daily (taken at same time).
Treatment-naive or switching from a delavirdine- or rilpivirine-containing regimen: initially saquinavir 500mg twice daily + ritonavir 100mg twice daily for 7 days, then increase to saquinavir 1g twice daily + ritonavir 100mg twice daily.
Children: <16yrs: not recommended.
200mg hard gel caps
tipranavir (TPV) Aptivus 250mg soft gel caps2 Adults: Tipranavir 500mg + ritonavir 200mg twice daily.
Children: <2yrs: not recommended.
Use oral soln if unable to swallow caps.
2−18yrs: tipranavir 14mg/kg + ritonavir 6mg/kg or (375mg/m² + ritonavir 150mg/m²) twice daily; max tipranavir 500mg + ritonavir 200mg twice daily.
Intolerance or toxicity (if virus not resistant to multiple PIs): may reduce dose to tipranavir 12mg/kg + ritonavir 5mg/kg or (290mg/m² + ritonavir 115mg/m²) twice daily.
100mg/
 
mL
oral soln4
Multiclass Fixed-Dose Combination
abacavir/
dolutegravir/
lamivudine
Triumeq 600mg/
 
50mg/
  300mg
tabs Adults: 1 tab daily. Concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, rifampin, carbamazepine: give additional dolutegravir 50mg separated by 12hrs from Triumeq.
Children: Not established.
atazanavir/
cobicistat
Evotaz 300mg/
 
150mg
tabs Adults: 1 tab daily.
Children: <18yrs: not established.
darunavir/
cobicistat
Prezcobix 800mg/
 
150mg
tabs Adults: 1 tab daily.
Children: <18yrs: not established.
efavirenz (EVF)/
emtricitabine (FTC)/
tenofovir disoproxil fumarate (TDF)
Atripla 600mg/
 
200mg/
  300mg
tabs Adults: ≥12yrs and ≥40kg: 1 tab once daily preferably at bedtime. Concomitant rifampin (≥50kg): Give additional 200mg/day of efavirenz.
Children: <12yrs: not recommended.
emtricitabine (FTC)/
rilpivirine/
tenofovir alafenamide (TAF)
Odefsey 200mg/
 
25mg/
  25mg
tabs Adults and Children: <12yrs (<35kg): not established. ≥12yrs (≥35kg): 1 tab once daily with food.
Severe renal impairment (CrCl <30mL/min): not recommended.
emtricitabine (FTC)/
rilpivirine/
tenofovir disoproxil fumarate (TDF)
Complera 200mg/
 
25mg/
  300mg
tabs Adults: ≥12yrs (and ≥35kg): 1 tab once daily with a meal. Renal impairment (CrCl<50mL/min): not recommended. Concomitant rifabutin: take additional rilpivirine 25mg once daily.
Children: <12yrs or <35kg: not established.
emtricitabine (FTC)/
tenofovir alafenamide (TAF)
Descovy 200mg/
 
25mg
tabs Adults and Children: <12yrs (<35kg): not established. ≥12yrs (≥35kg): 1 tab once daily.
Severe renal impairment (CrCl <30mL/min): not recommended.
elvitegravir/cobicistat/
emtricitabine (FTC)/
tenofovir alafenamide (TAF)
Genvoya 150mg/
 
150mg/
  200mg/10mg
tabs Adults and Children: <12yrs: not established. ≥12yrs and ≥35kg: 1 tab once daily with food.
Severe hepatic or renal impairment (CrCl <30mL/min): not recommended.
elvitegravir/
cobicistat/
emtricitabine
 (FTC)/
tenofovir disoproxil fumarate (TDF)
Stribild 150mg/
 
150mg/
  200mg/
   
300mg
tabs Adults: 1 tab once daily with food.
Renal impairment (CrCl <70mL/min): not recommended; discontinue if CrCl declines to <50mL/min during therapy. Severe hepatic impairment: not recommended.
Children: <18yrs: not recommended.
NOTES

Key: + = scored; PI = protease inhibitor

1Contains parabens, propylene glycol; 2Contains alcohol; 3Contains phenylalanine; 4Contains Vit. E 116 IU/mL; 5Keep in refrigerator

(Rev. 8/2016)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs